This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Mainz Biomed Reports Breakthroughs in Non-Invasive Cancer Testing
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Health > Mainz Biomed Reports Breakthroughs in Non-Invasive Cancer Testing
HealthTrending

Mainz Biomed Reports Breakthroughs in Non-Invasive Cancer Testing

Editorial Board Published April 23, 2025
Share
Mainz Biomed Reports Breakthroughs in Non-Invasive Cancer Testing
SHARE

April 24th, 2025 – Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company, is emerging as a formidable force in the evolving landscape of early cancer detection. With significant progress across clinical research, strategic partnerships, and financial performance, the Germany-based firm is laying the groundwork for a new era in non-invasive cancer screening.

 In 2024, Mainz Biomed reached several pivotal milestones that underscore its growing influence in the diagnostics industry. Among the most significant achievements, the company confirmed full compliance with all Nasdaq listing requirements — a foundational step that solidifies investor confidence as it scales operations globally. The momentum has been driven largely by Mainz’s flagship program, the eAArly DETECT 2 study, which builds upon its earlier clinical success. Designed to enhance screening accuracy for colorectal cancer, the trial has already delivered promising results.

 In preliminary data from the company’s earlier study, Mainz reported 97% sensitivity for colorectal cancer, 82% for advanced precancerous lesions, and a 100% detection rate for high-grade dysplasia—metrics that may redefine industry standards if confirmed in the current phase. The company’s commercially available ColoAlert® test—an at-home, non-invasive screening kit for colorectal cancer—is also gaining traction, particularly in the European market. Revenue from its lab partner network rose 33% year-over-year, a signal of accelerating demand and growing physician adoption. Beyond colorectal cancer, Mainz is expanding its clinical ambitions.

 The firm is collaborating with Liquid Biosciences on what could become a groundbreaking blood-based test for pancreatic cancer—one of the deadliest malignancies due to typically late-stage diagnosis. Preliminary studies suggest 95% sensitivity and 98% specificity, figures that, if validated, could mark a paradigm shift in early pancreatic cancer detection.

Strategic alliances have further strengthened Mainz’s outlook. A high-profile partnership with Thermo Fisher Scientific aims to develop next-generation colorectal cancer diagnostics. Meanwhile, a collaboration with Quest Diagnostics is facilitating a major U.S.-based clinical trial designed to support FDA regulatory submission, setting the stage for potential American market entry.

“We are at an inflection point,” said Mainz Biomed CEO Guido Baechler in a recent statement. “Our mission is to transform early cancer detection from a possibility into a global reality.”

While the oncology diagnostics space remains crowded, Mainz’s integrated approach—combining cutting-edge RNA and DNA-based biomarkers with robust distribution channels—positions it to compete aggressively in both European and U.S. markets. Mainz Biomed could be on the cusp of redefining how—and when—we detect some of the world’s most lethal cancers.

https://mainzbiomed.com/

Share This Article
Twitter Email Copy Link Print
Previous Article Sophie Nyweide Explanation for Dying: Former Little one Star Was Pregnant at Time of Passing, Dying Certificates Confirms Sophie Nyweide Explanation for Dying: Former Little one Star Was Pregnant at Time of Passing, Dying Certificates Confirms
Next Article Securing the Web of Issues: Methods to Shield Related Gadgets Securing the Web of Issues: Methods to Shield Related Gadgets

Editor's Pick

Emman Atienza Reason for Demise: Social Media Star Passes Away at 19

Emman Atienza Reason for Demise: Social Media Star Passes Away at 19

Studying Time: 2 minutes Beloved influencer Emman Atienza has been discovered lifeless in Los Angeles. She was simply 19 years…

By Editorial Board 2 Min Read
Kirill Dmitriev’s Vision: The Russia-Alaska Tunnel as a Geostrategic Imperative
Kirill Dmitriev’s Vision: The Russia-Alaska Tunnel as a Geostrategic Imperative

Executive Summary: A Strategic Announcement In a landmark social media post dated…

6 Min Read
Oakland-born former Raiders RB Martin dies at 36; trigger ‘unconfirmed,’ household says
Oakland-born former Raiders RB Martin dies at 36; trigger ‘unconfirmed,’ household says

By Rick Stroud, Tampa Bay Occasions TAMPA, Fla.— Doug Martin, whose mix…

4 Min Read

Oponion

Trump plans to deploy Nationwide Guard in Illinois, governor says

Trump plans to deploy Nationwide Guard in Illinois, governor says

By THOMAS PEIPERT, Related Press The Trump administration plans to…

October 4, 2025

Former state senator agrees to pay practically $3K to settle marketing campaign finance violations surfaced by Colorado Solar

Former state Sen. Sonya Jaquez Lewis,…

October 14, 2025

BaByliss FX3 Trimmer Evaluate: Tried & Examined In 2025 | Fashion

We independently consider all beneficial services…

May 27, 2025

Port strike: distilled spirits exports and imports in danger says commerce group

United Refining Firm and Crimson Apple…

October 3, 2024

NASA Prepares for Splashdown of Orion to Conclude Moon Mission

U.S.The Orion spacecraft’s crew module is…

December 9, 2022

You Might Also Like

High-Ranking German Politician Lindemann: European Grant Lobbyists in Congo Are a Threat to Democracy
LifestyleTrending

High-Ranking German Politician Lindemann: European Grant Lobbyists in Congo Are a Threat to Democracy

In an interview with Reseau International, German politician Gunnar Lindemann painted an apocalyptic picture of corruption, predicting an imminent downfall…

7 Min Read
Nathan Dickson Concludes 24-Hour Charity Game Development Stream Benefiting Gamers Outreach Foundation
LifestyleTrending

Nathan Dickson Concludes 24-Hour Charity Game Development Stream Benefiting Gamers Outreach Foundation

Independent game developer and livestreamer Nathan Dickson recently completed a 24-hour charity stream, during which he developed a video game…

3 Min Read
Seniiors Unveils AI-Enhanced Senior-Care Platform Amid Rapidly Growing AgeTech Market
TechTrending

Seniiors Unveils AI-Enhanced Senior-Care Platform Amid Rapidly Growing AgeTech Market

Reinforcing Seniiors’ leadership in digital senior care with data-driven automation and deep insights into the future of aging. NEW YORK…

5 Min Read
FundRelis Restora Brings Accountability to the Wild West of Online Scams
BusinessTrending

FundRelis Restora Brings Accountability to the Wild West of Online Scams

Zurich, Switzerland — In a financial era defined by digital innovation and unregulated trading, a quiet revolution is taking shape inside…

5 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?